Retatrutide vs Tirzepatide — the Core Difference
The defining difference is receptor coverage: Tirzepatide is a dual GIP/GLP-1 agonist, while Retatrutide is a triple agonist that also engages the glucagon receptor. That third target changes the experimental profile and is the reason labs treat them as distinct compounds rather than interchangeable options.
Both are synthetic, fatty-acid-acylated peptides in the same metabolic-research family, and both share the same sourcing and purity expectations. The choice between them is driven by your protocol’s receptor targets, not by price.
Side-by-Side Comparison
- Tirzepatide: 39 amino acids, MW 4813.5 Da, GIP + GLP-1 receptor agonist
- Retatrutide: ~44 amino acids, MW ~4840 Da, GIP + GLP-1 + glucagon receptor agonist
- Shared: both are lyophilized, require -20°C storage, and need ≥98% HPLC with MS confirmation
Which One Should Your Lab Order?
Order Retatrutide if your protocol specifically requires glucagon-receptor engagement; order Tirzepatide if dual GIP/GLP-1 agonism matches your experimental design. If you’re comparing them head-to-head, source both from the same supplier so the purity and fill-weight variables are held constant.
FAQ
Is Retatrutide stronger than Tirzepatide?
In preclinical research terms, “stronger” isn’t the right framing — the two compounds activate different receptor sets. Retatrutide adds glucagon-receptor activity, which changes the experimental readout rather than simply amplifying the dual-agonist effect.
Do Retatrutide and Tirzepatide have the same molecular weight?
No — Tirzepatide is 4813.5 Da and Retatrutide is approximately 4840 Da. Mass spec must match the specific compound you ordered.
Important: All products are sold strictly for laboratory and research purposes only — not for human or veterinary use. No medical or dosing guidance is provided.